Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting

Circulation

Volumn 108, Issue 17, 2003, Pages 2074-2081

  Piatti, PierMarco ^a,c   Di Mario, Carlo ^a   Monti, Lucilla D ^a   Fragasso, Gabriele ^a   Sgura, Fabio ^a   Caumo, Andrea ^a   Setola, Emanuela ^a   Lucotti, Pietro ^a   Galluccio, Elena ^a   Ronchi, Cristina ^a   Origgi, Anna ^a   Zavaroni, Ivana ^b   Margonato, Alberto ^a   Colombo, Antonio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c Medicine Division   (Italy)

Author keywords

Coronary disease; Diabetes mellitus; Metabolism; Nitric oxide; Restenosis

Indexed keywords

GLUCOSE; INSULIN; LEPTIN; NITRATE; NITRIC OXIDE; NITRITE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORONARY STENT; CORRELATION FUNCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR;

AREA UNDER CURVE; BLOOD GLUCOSE; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; MIDDLE AGED; NITRIC OXIDE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; STENTS; VASCULAR PATENCY;

EID: 0242381316     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000095272.67948.17     Document Type: Article

References (34)

1. Takagi T, Akasaka T, Yamamuro A, et al. Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation: intravascular ultrasound studies. J Diabetes Complications. 2002;16:50-55.
2. Lefroy DC, Crake T, Uren NG, et al. Effects of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation. 1993;88:43-54.
3. Yao S-H, Ober JC, Krishnaswami A, et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation. 1992;86:1302-1309.
4. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;83:1774-1777.
5. Wallace AM, Mc Mahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104:3052-3056.
6. Lembo G, Vecchione C, Fratta L, et al. Leptin induced direct vasodilation through distinct endothelial mechanisms. Diabetes. 2000:49:293-297.
7. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes. 2002;51:168-173.
8. Piatti P, Fragasso G, Monti LD, et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol. 1999;34:1452-1460.
9. Verdon CP, Burto BA, Prior RL. Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+: when the Griess reaction is used to assay for nitrite. Anal Biochem. 1995;224:502-508.
10. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
11. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes. 1989;38:1512-1527.
12. Caumo A, Bergman RN, Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. J Clin Endocrinol Metab. 2000;85:4396-4402.
13. Breda E, Cavaghan MK, Toffolo G, et al. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes. 2001;50:150-158.
14. Piatti PM, Monti LD, Zavaroni I, et al. Alteration in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab 2000;85:2416-2420.
15. Zavaroni I, Piatti PM, Monti LD, et al. Plasma nitric oxide concentrations are elevated in insulin-resistant healthy subjects. Metabolism. 2000;49:959-961.
16. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000;101:1780-1784.
17. Monti LD, Barlassina C, Citterio L et al. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes. 2003;52:1270-1275.
18. Myers PR, Webel R, Thondapu V, et al. Restenosis is associated with decreased coronary artery nitric oxide synthase. Int J Cardiol. 1996;55:183-191.
19. Wu TC, Chen YH, Chen JW, et al. Impaired forearm reactive hyperemia is related to late restenosis after coronary stenting. Am J Cardiol. 2000;85:1071-1076.
20. Ikeda U, Yamamoto K, Maeda Y, et al. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension. 1997;29:65-69.
21. Piatti PM, Fragasso G, Monti LD, et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimetylarginine levels. Circulation. 2003;107:429-436.
22. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation. 2002;106:1904-1905.
23. Recchia FA, Vogel TR, Hintze TH. NO metabolites accumulate in erythrocyte in proportion to carbon dioxide and bicarbonate concentration. Am J Physiol Heart Circ Physiol. 2000;279:H852-H856.
24. Yamagishi SI, Edelstein D, Du XL, et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-I expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001;276:25096-25100.
25. Doehner, Rauchhaus M, Godsland IF, et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinemia, but not to norepinephrine or TNF-alpha. Int J Cardiol. 2002;83:73-81.
26. Soderberg S, Stegmayr B, Ahlbeck-Glaber C, et al. High leptin levels are associated with stroke. Cerebrovasc Dis. 2003;15:63-69.
27. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40:1935-1942.
28. Schillinger M, Exner M, Mlekusch W, et al. Acute-phase response after stent implantation in the carotid artery: association with 6-month in-stent restenosis. Radiology. 2003;227:516-521.
29. Takagi T, Yoshida K, Akasaka T, et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in non diabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:731-738.
30. Iozzo P, Chareonthaitawee P, Dutka D, et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes. 2002;51:3020-3024.
31. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3-19.
32. Bergman RN, Finegood DT, Kanh SE. The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest. 2002;32(suppl 3):35-45.
33. The Decode Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-621.
34. Norhammar A, Tenerz A, Nilsson G. et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144.